Descripción
<p><strong>Afterwork Event: Carve‑Outs in Pharma and Beyond</strong></p> <p>📍 <em>Campus Biotech, Geneva</em></p> <p>📅 <em>Thursday, October 1, 2026</em></p> <p>Join us for an exclusive evening co‑hosted by <strong>Swiss Healthcare Licensing Group (Swiss HLG)</strong> and <strong>Gyrus Capital</strong> to explore one of the most powerful value creation strategies in healthcare and life sciences: <strong>carve-outs</strong>.</p> <p>By separating non-core assets or businesses into independent companies, carve-outs can unlock hidden value, sharpen strategic focus, and create platforms for sustainable growth.</p> <p> </p> <p>🎤 <strong>Keynote Speaker:</strong></p> <ul> <li><strong>Etienne Jornod</strong>: Executive Chairman of OM Pharma, Former Executive Chairman Galenica and Vifor, Former Chairman NZZ and Director Alliance Boots (KKR), will share insights from the successful spin‑out of OM Pharma from Vifor and the lessons learned from this transformative transaction.</li> </ul> <p>💡 <strong>Market and Strategic Insights:</strong></p> <ul> <li><strong>Elsa Torchet</strong>: Director, Life Sciences, Strategy and Business Design, Deloitte</li> <li><strong>Igor Heinzer</strong>: Partner – Head of Valuation and Modelling, Deloitte</li> </ul> <p><strong>💼</strong><strong> Investor and Operational Insights:</strong></p> <ul> <li><strong>Becki Morison</strong>: CEO, Essential Pharma</li> <li><strong>Robert Watson</strong>: Co-founder, Gyrus Capital</li> </ul> <p><strong>🍸</strong><strong> Networking Apéro:</strong></p> <p>Continue the conversation over drinks and refreshments while connecting with peers from Switzerland's healthcare, biotech, pharmaceutical, and investment communities.</p> <p>🕔 <strong>Schedule:</strong></p> <ul> <li>Doors open: 5:00 PM</li> <li>Presentations: 5:30 – 7:00 PM</li> <li>Networking apéro: from 7:00 PM</li> </ul> <p> </p> <p><strong><em>Bios</em></strong></p> <p><strong>Etienne Jornod: Executive Chairman of OM Pharma, Former Executive Chairman Galenica and Vifor, Former Chairman NZZ and Director Alliance Boots (KKR)</strong></p> <p>Etienne Jornod has been the Executive Chairman and Co-owner of OM Pharma since October 2020. Mr Jornod founded Optimus Holding with the goal of buying OM Pharma along with other Swiss entrepreneurs and the Turkish pharmaceutical leader Abdi Ibrahim. The ambition is to further expand OM Pharma and invest in R&D to exploit the full potential of its bacterial extracts.</p> <p>In order to do this, Mr Jornod stepped down as Executive Chairman of Vifor Pharma's Board of Directors early 2020, making a public offer for OM Pharma which was then a Vifor Pharma affiliate. To avoid any conflict of interest, the sales process was managed by Rothschild. </p> <p>Mr Jornod spent all of his career at Galenica-Vifor Group, were he started as Junior Product Manager at the age of 22. In 1995, he became Chairman and CEO of the Galenica Group, which took the name of the Vifor Pharma Group in 2017. Under his management the Group grew from a wholesaler, solely reserved for Swiss pharmacists, to a global group focused on two main activities: Vifor Pharma (Global Speciality Pharma Company) and Galenica Santé (Pharmacy Chain with Services and Products). In 2017, the Vifor Pharma Group sold Galenica Santé on the stock market via an IPO. Both groups were valued at more than CHF14 billion on Mr Jornod’s retirement. For 10 years, until April 2023, Mr Jornod was Chairman of the Board of Directors of the NZZ-Mediengruppe. During his career, Mr Jornod has also been a member of the board of numerous private and listed companies, such as AllianceUnichem (Footsee), AllianceBoots (KKR), Bieffe Medital, Bon Appétit and Vaudoise.</p> <p>Mr Jornod holds a degree in business and economics from HEC Lausanne (lic. oec.) and graduated from the Senior Executive Program at Stanford University.</p> <p> </p> <p><strong>Elsa Torchet: Director, Life Sciences, Strategy and Business Design, Deloitte</strong></p> <p>Elsa is a Director in Deloitte’s Life Sciences practice with 10 years of experience working in a mid-size listed company and consulting. She advises executives on a diverse array of topics, including growth strategy, transformation, risk, and business development, with a particular focus on the precision medicine ecosystem. Elsa’s clients span regional, international, global, listed organisations, as well as privately owned and family businesses. In her advisory role, Elsa collaborates with her clients to navigate complex challenges, delivering innovative and high-quality services, and driving strategic market development. </p> <p> </p> <p><strong>Igor Heinzer: Partner – Head of Valuation and Modelling, Deloitte</strong></p> <p>Igor is a partner in Strategy & Transactions with more than 25 years of international experience and leads the Valuation and Business Modelling practice of Deloitte Switzerland. He has advised emerging growth companies and global leaders across the pharmaceutical, biotechnology, medtech, diagnostics and broader life sciences sector. His experience spans M&A and licensing transactions, intellectual property valuation, growth and scale-up strategies, fundraising, capital allocation, financial and tax reporting, and performance tracking. Igor regularly advises corporate development teams, C-suite executives and Boards on the financial and valuation implications of strategic decisions, investments and disruptive technologies. </p> <p> </p> <p><strong>Becki Morison: CEO, Essential Pharma</strong></p> <p>Becki is a seasoned global executive with more than 25 years of experience in the pharmaceutical industry, spanning commercial leadership, market access, and large-scale organisational transformation. She is currently CEO of Essential Pharma, an international specialty pharma company. Over her career, Becki has held senior leadership roles at LEO Pharma and Eli Lilly, where she led global commercial functions, major therapeutic franchises, and country and regional organisations across Europe, Asia-Pacific, and the US. She has a track record of leading businesses through periods of significant strategic change and building high-performing teams across markets.</p> <p> </p> <p><strong>Robert Watson: Co-founder, Gyrus Capital</strong></p> <p>Dr. Robert Watson is the co-founder of Gyrus Capital, a Geneva-based, healthcare-focused private equity firm, and has over 20 years of investment experience in the pharma and life sciences sector. Over his career, Rob has led healthcare and life sciences investments across Europe, the US, and Asia, holding senior roles at leading investment firms in New York, London, Geneva, and Paris, including as Managing Director at Altaris Capital Partners.</p>